These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10921399)

  • 1. Hepatitis C: retreatment and treatment of patients with renal failure.
    Chow WC
    J Gastroenterol Hepatol; 2000 May; 15 Suppl():E152-5. PubMed ID: 10921399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group.
    Cavalletto L; Chemello L; Donada C; Casarin P; Belussi F; Bernardinello E; Marino F; Pontisso P; Gatta A; Alberti A
    J Hepatol; 2000 Jul; 33(1):128-34. PubMed ID: 10905596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.
    Shiffman ML; Hofmann CM; Gabbay J; Luketic VA; Sterling RK; Sanyal AJ; Contos MJ; Ryan MJ; Yoshida C; Rustgi V
    Am J Gastroenterol; 2000 Oct; 95(10):2928-35. PubMed ID: 11051370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data.
    Cammà C; Bruno S; Schepis F; Lo Iacono O; Andreone P; Gramenzi AG; Mangia A; Andriulli A; Puoti M; Spadaro A; Freni M; Di Marco V; Cino L; Saracco G; Chiesa A; Crosignani A; Caporaso N; Morisco F; Rumi MG; Craxì A
    Gut; 2002 Dec; 51(6):864-9. PubMed ID: 12427791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
    Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G
    Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness of response-guided therapy using pegylated interferon and ribavirin for chronic hepatitis C virus infection in patients on maintenance dialysis.
    Goel A; Bhadauria DS; Kaul A; Prasad N; Gupta A; Sharma RK; Rai P; Aggarwal R
    Nephrology (Carlton); 2017 Sep; 22(9):706-711. PubMed ID: 27286895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
    Scott LJ; Perry CM
    Drugs; 2002; 62(3):507-56. PubMed ID: 11827565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study.
    Barbaro G; Di Lorenzo G; Soldini M; Giancaspro G; Bellomo G; Belloni G; Grisorio B; Annese M; Bacca D; Francavilla R; Rizzo G; Barbarini G
    Am J Gastroenterol; 1998 Dec; 93(12):2445-51. PubMed ID: 9860407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France.
    Pol S; Couzigou P; Bourlière M; Abergel A; Combis JM; Larrey D; Tran A; Moussalli J; Poupon R; Berthelot P; Bréchot C
    J Hepatol; 1999 Jul; 31(1):1-7. PubMed ID: 10424277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
    Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
    Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378].
    Veldt BJ; Brouwer JT; Adler M; Nevens F; Michielsen P; Delwaide J; Hansen BE; Schalm SW;
    BMC Gastroenterol; 2003 Aug; 3():24. PubMed ID: 12948399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-alpha2a/ribaviran versus interferon-alpha2a alone for the retreatment of hepatitis C patients who relapse after a standard course of interferon.
    Chapman BA; Stace NH; Edgar CL; Bartlett SE; Frampton CM; Scahill SL; Jennings LC
    N Z Med J; 2001 Mar; 114(1128):103-4. PubMed ID: 11346153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of standard antiviral therapy retreatment following interferon treatment failure in chronic hepatitis C patients].
    Liu JP; Kang Y; Shang J; Ding GQ; Xiao EH; Wei JF; Cao Q
    Zhonghua Gan Zang Bing Za Zhi; 2013 Sep; 21(9):656-8. PubMed ID: 24160338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Retreatment options for patients with chronic hepatitis C].
    Hrstić I; Ostojić R; Vucelić B
    Acta Med Croatica; 2009 Dec; 63(5):417-22. PubMed ID: 20198901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience.
    Alsaran K; Sabry A; Molhem A
    Ren Fail; 2013; 35(10):1305-9. PubMed ID: 24059964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon.
    Almasio PL; Di Marco V; Bonura C; Fuschi P; Camma C; Lo Iacono O; Artini M; Natoli C; Di Stefano R; Levrero M; Craxi A
    Dig Dis Sci; 1999 May; 44(5):1013-9. PubMed ID: 10235612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance.
    Rocha CM; Perez RM; Narciso JL; Ferreira AP; Lemos LB; Medina-Pestana JO; Silva AE; Ferraz ML
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):119-23. PubMed ID: 17272996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone.
    Min AD; Jones JL; Esposito S; Lebovics E; Jacobson IM; Klion FM; Goldman IS; Geders JM; Tobias H; Bodian C; Bodenheimer HC
    Am J Gastroenterol; 2001 Apr; 96(4):1143-9. PubMed ID: 11316161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review.
    Shepherd J; Waugh N; Hewitson P
    Health Technol Assess; 2000; 4(33):1-67. PubMed ID: 11134916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.